← Human Trials & Peer-Reviewed Studies
Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial
Plain-language guide to PMID 28019683 (2017): open-label randomized controlled trial study of Teriparatide in 224 patients.
Key Facts
- PMID
- 28019683
- Journal
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Malouf-Sierra J et al. (14 authors)
- DOI
- 10.1002/jbmr.3067
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Teriparatide, published as a randomized controlled trial.
Primary endpoint was change from baseline in lumbar spine (LS) BMD at 78 weeks.
Secondary and exploratory endpoints were change in BMD at the proximal femur, function, hip pain (Charnley score and 100 mm Visual Analog Scale [VAS]), quality of life (Short Form-36), radiology outcomes, and safety.
Who Took Part
According to the abstract, 224 patients were involved.
The age groups tagged for this paper are older adults and people over 80.
Patients with BMD T-score ≤ -2.0 and 25OHD ≥9.2 ng/mL were randomized to receive 26-week double-dummy treatment plus calcium and vitamin D, followed by 52-week open-label treatment with the same assigned active drug.
How the Study Was Run
The researchers set it up as a randomized and open-label study.
Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.
Nothing was hidden in this open-label Teriparatide study: the patients and staff both knew the treatment.
What Was Measured
Primary endpoint was change from baseline in lumbar spine (LS) BMD at 78 weeks.
Secondary and exploratory endpoints were change in BMD at the proximal femur, function, hip pain (Charnley score and 100 mm Visual Analog Scale [VAS]), quality of life (Short Form-36), radiology outcomes, and safety.
PubMed files the paper under topics including Hip Fractures, Risedronic Acid and Teriparatide.
Author keywords: BISPHOSPHONATES, BONE MINERAL DENSITY, FRACTURE RECOVERY and PERTROCHANTERIC HIP FRACTURE.
What This Means in Plain Language
The paper is a randomized and open-label study of Teriparatide in 224 patients.
The publication is from 2017 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.